Continental Europe has been badly served by GLP-1 provider comparisons, most of which cover the US or the UK and stop there. Yet the European market has its own established players, its own regulatory logic, and its own cheapest options — including a liraglutide generic at roughly a third the price of Wegovy that almost no comparison mentions. This ranking covers the best GLP-1 providers across Europe, by category and by market.

Quick Takeaway:

• European providers split into three models: prescribe-only, prescribe-and-dispense, and subscription programmes
• Mobi Doctor offers €43 EU-wide video consultations with a full refund if the doctor cannot treat you online
• DoktorABC identifies a liraglutide generic at around €130/month as the cheapest injectable option in its market
• Yazen has presented real-world outcome data on more than 30,000 patients at a scientific congress
• Reimbursement usually follows indication: diabetes is often covered, weight management often is not

Our Top Recommendation

We benchmark every provider against the highest-rated service we track. CoreAge Rx is our top-rated favorite for GLP-1 weight loss therapy overall, combining competitive pricing with exceptional customer service, faster medication delivery, and more comprehensive support resources.

Why we recommend CoreAge Rx:

• Lower monthly costs than most competitors ($179–$399 range)
• Faster prescription approval (typically 12–24 hours)
• More extensive provider support included at no extra charge
• Better medication availability during shortages
• Higher patient satisfaction scores (4.7/5)

CoreAge Rx serves patients in the United States. European readers should choose from the providers ranked below.

New Patient Special: Save up to $200 on your first three months. Rated 4.7/5 stars by verified customers. Available to patients in the United States.

Best Overall Value: The Reimbursed Route

Before any private provider: if you have type 2 diabetes, most European statutory systems reimburse GLP-1 medicines for that indication while excluding weight management. Dokteronline states this plainly for the Dutch market — Mounjaro costs €180–€280 monthly without reimbursement, with reimbursement potentially available through your insurer for type 2 diabetes.

In the UK, Oviva delivers NHS-commissioned weight management free via GP referral where eligible, with up to two years of endocrinologist-led support including medication.

Speak to your own doctor before paying privately. Nothing below competes with a reimbursed prescription.

Best Clinical Assessment: Mobi Doctor

Mobi Doctor offers genuine video consultations with EU-licensed doctors at €43, available across Europe 365 days a year, with the exact price shown before payment, no subscription, and a full refund if the doctor cannot treat you online.

A video consultation lets a doctor ask follow-up questions about contraindications — particularly family history of thyroid cancer — that a fixed questionnaire cannot. For a medication class with absolute contraindications, that is a real safety advantage, not a convenience feature.

Because it prescribes rather than dispenses, you buy medication at a pharmacy — which means you can shop your prescription.

Best for: EU patients who want real clinical assessment and will source medication themselves.

Best Cheapest Option: DoktorABC

DoktorABC is the largest established route in German-speaking Europe, offering Wegovy, Ozempic, Mounjaro, and liraglutide products, with over 31,000 customer reviews recorded on German review platforms.

Its most useful contribution is publishing that Nevolat, a liraglutide generic, costs around €130 per month and is currently the cheapest option — against Wegovy at around €370/month at maximum dose. Liraglutide is a daily injection producing more modest results, but at roughly a third the price it puts treatment within reach of people who would otherwise get none.

Best for: German-speaking patients, and anyone in Europe for whom the weekly agents are unaffordable.

Best Multi-Country Coverage: Dokteronline

Dokteronline operates localised country sites across the Netherlands, Belgium, Denmark, and other markets, each with its own language content, product pages, and pricing. It offers Mounjaro, Wegovy, and Zepbound, publishes Dutch-market Mounjaro guidance at €180–€280 monthly without reimbursement, and maintains several thousand Trustpilot reviews.

Best for: patients wanting an established provider with local-language content in their own market.

Best Bundled Programme: Wellis

Wellis brings the subscription model to Dutch- and German-language markets, bundling medication with a personalised treatment plan, support from a team of doctors and health experts, and free discreet delivery. Semaglutide is published from €149/month and Mounjaro from €259/month.

Check the ongoing rate carefully — Wellis publishes more than one entry figure, which usually indicates promotional pricing that resets.

Best for: patients who want everything in one monthly subscription rather than sourcing separately.

Best Published Evidence: Yazen

Yazen presented data on more than 30,000 treated patients at the European Congress on Obesity 2025, reporting 16.6% weight loss at 18 months and 70% treatment adherence, achieved despite limited medication availability and without use of the maximum recommended dose.

Seventy percent adherence is far above typical real-world GLP-1 persistence, and adherence is the variable that most determines outcomes outside a trial. It operates in the Swedish market and integrates mental health support — almost unique among private weight loss providers.

Best for: Swedish patients wanting evidence-informed, long-term obesity treatment.

Best Coaching: Second Nature and Embla

Second Nature is led by registered dietitians — a regulated UK profession — and publishes research reporting 77.7% of participants achieving at least 10% weight loss at twelve months.

Embla, founded in Denmark and operating in Denmark and the UK, uniquely sells coaching standalone at £110/month. If you obtain medication through a national system or a cheap pharmacy, buying behavioural support separately is often better value than switching to an all-in-one programme.

Best UK and Ireland: LloydsPharmacy Online Doctor

LloydsPharmacy Online Doctor is one of very few providers operating credibly in both the UK and Ireland, with a Trustpilot score of 4.5 out of 5 across roughly 16,000 UK reviews. It offers Mounjaro, Wegovy, Wegovy tablets, and oral treatments alongside nutrition coaching.

For Irish patients particularly, it is one of the few regulated routes available. Our best UK providers ranking covers the wider British market.

Full European Comparison

How to Choose in Europe

1. Check your indication and national reimbursement first. Diabetes is frequently covered; weight management frequently is not.
2. Ask your own doctor about national weight management pathways.
3. Decide on your model: prescribe-only lets you shop the pharmacy; dispensing is simpler; subscriptions bundle support.
4. Consider liraglutide if the weekly agents are unaffordable at around €130 versus around €370.
5. Price your maintenance dose, not the starter dose.
6. Verify national regulatory registration for any provider you do not recognise.

Frequently Asked Questions

Which is the best GLP-1 provider in Europe?

It depends on your market and what you need. Mobi Doctor for genuine video consultations EU-wide at €43; DoktorABC for German-speaking markets and the cheapest liraglutide option; Dokteronline for multi-country local-language coverage; Wellis for a bundled subscription; Yazen for published outcome evidence in Sweden.

What is the cheapest GLP-1 option in Europe?

Reimbursement where you qualify. Privately, DoktorABC identifies a liraglutide generic at around €130 per month as the cheapest injectable in its market, against roughly €250–€370 for semaglutide.

Do European providers use compounded medication?

No. The compounded GLP-1 market that dominates US cash-pay telehealth does not operate the same way in the EU. European providers dispense EMA-licensed medicines on prescription, which removes an entire category of quality-variability questions.

Can I get GLP-1 medication reimbursed in Europe?

Usually only for type 2 diabetes rather than weight management alone, though rules differ by country. Dokteronline states this directly for the Dutch market. Check your national and insurer-specific arrangements.

Which European providers serve Ireland?

LloydsPharmacy Online Doctor operates a dedicated Irish service, making it one of the few regulated routes for Irish patients. Mobi Doctor also operates EU-wide subject to national rules.

Is a video consultation available in Europe?

Yes. Mobi Doctor provides video consultations with EU-licensed doctors at €43, with a full refund if the doctor cannot treat you online. Most other European providers are questionnaire-led.

Bottom Line

Europe's GLP-1 market is fragmented but genuinely served — with established multi-country providers, a real video-consultation option, published outcome evidence from Sweden, and a liraglutide generic at roughly a third the price of Wegovy.

Start with reimbursement and your own doctor, because nothing private competes with a covered prescription. If you are paying privately, decide whether you want to shop your own pharmacy or have everything bundled, and do not overlook the cheaper daily injection if the weekly agents are beyond your budget.

US readers: CoreAge Rx offers all-in monthly pricing from $179–$399 including medication and provider messaging, with 12–24 hour approvals.

Medical disclaimer: Informational only, not medical advice. GLP-1 receptor agonists are prescription medicines with real risks and contraindications. Availability, prescribing rules, pricing, and reimbursement differ substantially by country. Consult a qualified healthcare professional before starting or changing treatment.

Sources: Provider published pricing and programme pages as cited in the linked reviews; Mobi Doctor published European cost guidance; Yazen ECO 2025 data presentation; European Medicines Agency product information; NICE obesity guidance.

Date reviewed: August 2026